Extracellular histones activate autophagy and apoptosis via mTOR signaling in human endothelial cells by Ibáñez Cabellos, Jose Santiago et al.
Accepted Manuscript
Extracellular histones activate autophagy and apoptosis via
mTOR signaling in human endothelial cells
José Santiago Ibañez-Cabellos, Carmen Aguado, Daniel Pérez-
Cremades, José Luis García-Giménez, Carlos Bueno-Betí, Eva
M. García-López, Carlos Romá-Mateo, Susana Novella, Carlos




To appear in: BBA - Molecular Basis of Disease
Received date: 8 February 2018
Revised date: 22 June 2018
Accepted date: 6 July 2018
Please cite this article as: José Santiago Ibañez-Cabellos, Carmen Aguado, Daniel Pérez-
Cremades, José Luis García-Giménez, Carlos Bueno-Betí, Eva M. García-López, Carlos
Romá-Mateo, Susana Novella, Carlos Hermenegildo, Federico V. Pallardó , Extracellular
histones activate autophagy and apoptosis via mTOR signaling in human endothelial cells.
Bbadis (2018), doi:10.1016/j.bbadis.2018.07.010
This is a PDF file of an unedited manuscript that has been accepted for publication. As
a service to our customers we are providing this early version of the manuscript. The
manuscript will undergo copyediting, typesetting, and review of the resulting proof before
it is published in its final form. Please note that during the production process errors may

















Extracellular histones activate autophagy and apoptosis via mTOR signaling in 
human endothelial cells  
 
José Santiago Ibañez-Cabellos1,2*, Carmen Aguado1,3*, Daniel Pérez-Cremades2*, 
José Luis García-Giménez1,2*, Carlos Bueno-Betí2, Eva M. García-López2, Carlos 
Romá-Mateo1,2,4, Susana Novella2, Carlos Hermenegildo2#, Federico V. Pallardó1,2#. 
 
1 Center for Biomedical Network Research on Rare Diseases (CIBERER). Institute of 
Health Carlos III. Valencia (Spain)- INCLIVA-CIPF Joint Unit in Rare Diseases. 
2 Department of Physiology. Faculty of Medicine and Dentistry. University of Valencia 
and INCLIVA Biomedical Research Institute. Valencia (Spain). 
3 Centro de Investigación Príncipe Felipe (CIPF). Valencia (Spain). INCLIVA-CIPF Joint 
Unit in Rare Diseases 
4Epigenetics Research Platform, CIBERer-UV-INCLIVA, Valencia, (Spain) 
* José Santiago Ibañez-Cabellos, Carmen Aguado, Daniel Pérez-Cremades and José 
Luis García-Giménez have contributed equally to this work 
 
#Correspondence: 
Dr. Federico V. Pallardó and Dr. Carlos Hermenegildo 
University of Valencia 
Department of Physiology 
Av/ Blasco Ibañez, 15 




















Circulating histones have been proposed as targets for therapy in sepsis and 
hyperinflammatory symptoms. However, the proposed strategies have failed in clinical 
trials. Although different mechanisms for histone-related cytotoxicity are being 
explored, those mediated by circulating histones are not fully understood. Extracellular 
histones induce endothelial cell death, thereby contributing to the pathogenesis of 
complex diseases such as sepsis and septic shock. Therefore, the comprehension of 
cellular responses triggered by histones is capital to design effective therapeutic 
strategies. Here we report how extracellular histones induce autophagy and apoptosis 
in a dose-dependent manner in cultured human endothelial cells. In addition, we 
describe how histones regulate these pathways via Sestrin2/AMPK/ULK1-mTOR and 
AKT/mTOR. Furthermore, we evaluate the effect of Toll-like receptors in mediating 
autophagy and apoptosis demonstrating how TLR inhibitors do not prevent apoptosis 
and/or autophagy induced by histones. Our results confirm that histones and 
autophagic pathways can be considered as novel targets to design therapeutic 
strategies in endothelial damage.  
 
Highlights 
1. Extracellular histones induce autophagy and apoptosis in HUVEC, in a dose 
dependent manner 
2. Histones impair the expression of upstream regulators of mTOR-mediated 
pathways 
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1. Introduction  
Histones are essential proteins that participate in the conformation of chromatin and in 
the regulation of gene expression. Histones contribute to epigenetic regulation by 
means of post-translational modifications (PTMs) in the histone tails. Surprisingly, as 
early as in the 1950’s James G. Hirsch described the activity of histones as 
antimicrobials [1]. In recent years, it has been shown that extracellular histones are 
toxic to cultured mouse intestinal epithelial cells in serum-free medium [2] and that they 
induce apoptosis in renal tubular epithelial cells [3] as well as in lymphocytes [4]. 
Furthermore, it has been demonstrated that severely damaged tissues release high 
amounts of nucleosomes (the basic structural unit of chromatin composed by histones 
and DNA) as well as free histones into the bloodstream, aggravating the clinical 
features of a trauma [5]. In fact, Abrams et al. demonstrated that circulating histones 
act as mediators for distant organ damage (i.e. lungs) through interaction with 
membrane phospholipids, causing cellular calcium influx. Corroborating those 
observations, histones released into the bloodstream were found in patients with 
severe blunt trauma, pancreatitis, and sepsis [5, 6], and also in disseminated 
intravascular coagulation [7]. Based on these pathological properties, extracellular 
nucleosomes and histones are considered pathogen-associated molecular patterns 
(PAMPs) and damage-associated molecular patterns (DAMPs). These molecules are 
able to activate the innate immune system through Toll-like receptors (TLRs). In this 
scenario, the deregulation of the innate immune system triggered by the presence of 
PAMPs may also produce alterations in the endothelium [8]. Moreover, TLRs are also 
found in endothelial cells, being involved in the physiopathology of sepsis by regulating 
and activating inflammatory signaling, coagulopathy and vascular permeability [9]. 
Once activated by TLRs, endothelial cells were found to secrete mediators including 
cytokines, chemokines, reactive oxygen species (ROS) and nitric oxide, promoting also 
the secretion of cell surface proteins such as ICAM-1 [8]. Furthermore, inflammatory 
insults are known to activate innate immunity and propagate organ damage through the 
recognition of extracellular DAMP molecules. Therefore, considering the role of 
extracellular histones as PAMPs and DAMPs, and the multiple pathways which they 
can activate, they have been proposed as candidate biomarkers for diagnostic of 
sepsis, and consequently as novel therapeutic targets in human diseases [10]. 
Importantly, interactions between histones and TLRs have been related to cell death in 
some cell types [11, 12], but there is still scarce information about the signaling 
cascade mediated by extracellular histones through TLRs in human umbilical vein 
















The endothelium mediates the release of vasoactive mediators that control the 
vascular tone and is also involved in the maintenance of a balance between pro- and 
anti-apoptotic signals. Perturbation of this equilibrium may contribute to the 
pathogenesis of diverse diseases [13-16]. Histones have been detected in plasma of 
mice, baboons, and human patients with sepsis [6, 17], and they have been shown to 
induce endothelial cell death during septic shock; however, there is limited information 
regarding the mechanism by which endothelial cells die. Endothelial apoptotic cells 
become pro-coagulant and pro-adhesive [18], resulting in changes in the integrity and 
function of the endothelium, and thereby participating in the pathogenesis of a variety 
of human diseases [16].  We have recently demonstrated in HUVEC that extracellular 
histones stimulate the release of endothelial-dependent mediators through an up-
regulation in the COX-2-PGIS-PGI2 pathway, which involves a COX-2-dependent 
superoxide production that downregulates eNOS and NO bioavailability, thereby 
contributing to endothelial cell dysfunction [19]. 
Therefore, if extracellular histones are cytotoxic towards the endothelium [6], they 
should probably mediate cellular responses contributing to worsening of the disease. 
As discussed above, several therapeutic strategies have failed in fighting sepsis and 
septic shock from a molecular approach [20], highlighting the possibility that elucidation 
of the mechanisms involved in histone-mediated cytotoxicity may contribute to a 
deepest and more detailed comprehension of the complex pathogenesis of sepsis. 
Hence, a fine dissection of the endothelial cellular responses triggered by histones will 
open the path to the design of therapeutic strategies, using circulating histones as 
prognosis biomarkers in those diseases where they are present. Here we describe the 
molecular landscape of histone-mediated autophagy and apoptosis in endothelial cells, 


















2. Material and methods 
2.1. Cell culture and experimental design 
Primary human umbilical vein endothelial cells (HUVEC) cultures were obtained from 
human umbilical cord from Hospital Clínico Universitario of Valencia as previously 
described [21]. Umbilical cords were obtained following the principles outlined in the 
Declaration of Helsinki and were approved by the Ethical Committee of Clinical 
Research of the INCLIVA, Hospital Clínico Universitario of Valencia. Written informed 
consent was obtained from all donors. Briefly, umbilical veins were treated with 1% 
collagenase (Life Technologies, Carlsbad, CA, USA) and HUVEC were cultured in 
endothelial growing media (EGM)-2 (Lonza, Barcelona, Spain) that contains 
Endothelial cell basal medium-2 and the following growth supplements: human 
Epidermal Growth Factor (hEGF), 0.1%; Vascular Endothelial Growth Factor (VEGF 
0.1%; R3-Insulin-like Growth Factor-1 (R3-IGF-1), 0.1%; Ascorbic Acid, 0.1%; 
Hydrocortisone, 0.04%; human Fibroblast Growth Factor-Beta (hFGF-β), 0,4%; 
Heparin (0.1%); Fetal Bovine Serum (FBS), 2%; Gentamicin/Amphotericin-B (GA), 
0.1%. 
HUVEC from passages 3 to 5 were used in this study. When they reached 80% of 
confluence, media was changed and cells were exposed during 4 h to different calf 
thymus (CT) histone concentrations (Sigma-Aldrich, St. Louis, MO, USA): 10, 25, 50 or 
100 µg/mL prepared in PBS pH 7.4 (Gibco, MS, USA). Lysosomal inhibitors used for 
the study of autophagy activation were 20 mM NH4Cl plus 0.1 mM leupeptin (treated 
during the last hour and a half) to inhibit LC3-II degradation as described in Rubinsztein 
et. al. [22]. For TLR inhibition, compunds used were: 3 µM CLI-095 as TLR-4 
antagonist (Invivogen, Tolouse, France); 0.7 µM iODN, as TLR-7/9 antagonist (Enzo 
Life Science, Farmingdale, NJ, USA); and OxPAPC 25 µg/mL (30 µM) (Sigma-Aldrich), 
as TLR-2 and TLR-4 antagonist. Compounds were added to HUVEC 1 h before histone 
treatments. 
 
2.2. Western blot 
After histone treatment cells were scraped on ice in lysis buffer [20mM Hepes pH 7.4, 
1% Triton X-100, 100mM NaCl, 50mM NaF, 10mM β-glycerophosphate, 1mM 
phenylmethylsulfonyl fluoride (PMSF), 1mM sodium orthovanadate, protease inhibitor 
cocktail (Roche Diagnostics, Barcelona, Spain)]. Proteins were denatured using the 
















mercaptoethanol 10%) and heated to 95°C for 5 min. Afterwards, samples were 
electrophoresed in a 12% SDS-PAGE and transferred onto nitrocellulose or PVDF 
membrane (Whatman GmbH, Dassel, Germany).  
After transference, the membrane was blocked with milk 5% or BSA 5% (in the case of 
phosphorylated proteins) in TBS-Tween (TBST) for 1 h. Afterwards, the membranes 
were incubated with specific primary antibodies recognizing LC3 (NB100-2220; Novus 
Biologicals, Abingdon, UK), Lamp2 (ab25631; Abcam; Cambridge, UK), Bax 
(GTX109683; GeneTex; Irvine, USA), Bcl-2 (2870), p70S6 kinase (9202), phospho-
p70S6 kinase (Thr389, #9205), AMPK (#2532), phospho-AMP kinase (Thr172, #2535), 
Akt (9272), phospho-Akt (Ser473, 9271), phospho-p53 (Ser15, #9284), ULK1 
(ab167139, Abcam; Cambridge, UK), phospho-ULK1 (Ser555, #5869), mTOR (#2972), 
phospho-mTOR (Ser2448, #2971) all from Cell Signalling Technology (Leiden, The 
Netherlands), sestrin 2 (sc-101249,Santa Cruz Biotech; Dallas, USA), beta-actin (A-
2066, Sigma-Aldrich; St Louis, USA). Blots were probed with anti-mouse or anti-rabbit 
IgG-HRP secondary antibody. Thereafter, the blots were washed again with TBST and 
further incubated for 1 h with a secondary mouse, rabbit or goat antibody conjugated 
with horseradish peroxidase-linked. The membrane was incubated at room 
temperature and constant agitation. Finally, the membrane was washed 3x5 min with 
TBST. To observe protein signals, Chemioluminiscent ECL Western Blotting Detection 
reagents (GE Healthcare, Hatfield and Hertfordshire, UK) was added onto the 
membrane, 1 ml/membrane, and membranes were revealed by an image reader LAS-
4000 (General Electric Healthcare, Uppsala, Sweden). Signal density was analysed 
with ImageJ software (NIH Image, National Institutes of Health, Bethesda, MD, USA). 
 
2.3. Apoptosis determination 
Apoptosis was determined by Annexin-V kit (Immunostep, Salamanca, Spain) following 
the manufacturer specifications. Culture media was recovered together with HUVEC 
previously exposed to desired treatments. Cells were resuspended in Annexin-V buffer 
and stained with Annexin-V-FITC and propidium iodide (PI) for 15 min in the dark. 
Then, stained cells were analyzed by flow cytometry by using a FACS-Verse cytometer 
(Beckton Dickinson, San Jose, CA, USA) and Infinicyt software (Cytognos, Santa 
Marta de Tormes, Salamanca, Spain). Apoptotic cells were also determined by 
fluorescence microscopy. Adhered HUVEC were stained with Annexin-V-PE 
(Immunostep, Salamanca, Spain) for 15 min. Counter staining was achieved by 
















obtained with an inverted fluorescence microscope Nikon Eclipse Ti (40x 
magnification). 
2.4. Confocal microscopy 
Confocal images were acquired using a Leica TCS-SP8 X confocal laser scanning unit 
(Leica Microsystems, Wetzlar, Germany). All images are maximum intensity projection 
from 10 optical slices in Z-dimension. HUVEC were seeded in 2 cm2 Lab-TeK II 
chambered cover glass (Nunc, Thermo Fischer Scientific, Waltham, MA, USA). The 
number of autophagic vacuoles was measured using immunofluorescence staining of 
endogenous LC3. Briefly, fixed cells with 4% paraformaldehyde in PBS for 10 min at 
room temperature and quenched with 75 mM NH4Cl and 25 mM glycine for 10 min, 
permeabilized with 0.3% Triton-X100 and blocked with blocking buffer (10 mg/ml de 
BSA, 4 % de FBS, 0.1 % de Triton-X100). Cell were incubated overnight at 4 ºC with 
anti-LC3 antibody (dilution 1:50) (Novus, NB100-2220). Coverslips were washed four 
times with PBS and incubated with secondary antibody solution consisting of 
AlexaFluor488-conjugated donkey anti-rabbit IgG secondary antibody (Invitrogen, 
1:500) for 1 h, at RT.  After extensively washing with PBS, the coverslips were 
mounted using DAPI Fluoromount-G (SouthernBiotech; Birmingham, AL, USA). 
Lysosomes were stained with LysoTracker Red DND-99 50x10-9M (Molecular Probes, 
Carlsbad, CA, USA) at 37 ºC for 30 min. The number of fluorescent dots corresponding 
to autophagolysosomes per cell were counted (at least 10 HUVEC cells) using ImageJ 
(National Institutes of Health) [23], as previously described by one of the authors [24].  
 
2.5. Statistical analysis 
For the statistical analysis of the results, the mean was taken as the measurement of 
the main tendency, while standard deviation was taken as the dispersion 
measurement. One-way analysis of variance was conducted in order to explore 
significant differences between groups. When an interaction effect was found, multiple 
comparisons using the Tukey post-hoc test was performed. The significance has been 
considered at *P<0.05, **P<0.01 and ***P<0.001, as indicated in each case. GraphPad 
Prism v5.0 (GraphPad Software, San Diego, CA, USA) was used for statistical analysis 

















3.1. Extracellular histones induce autophagy and apoptosis in a dose-
dependent manner in HUVEC  
In order to assess the dose-dependent activation of cellular damage, we analyzed the 
effect of increasing concentrations of extracellular histones, ranging from 10 to 100 
μg/mL. It has been previously described that circulating histones can damage 
mammalian cells. Abrams et al. found that the concentration of circulating histones 
ranges between 10 to 230 μg/mL within 4 h after lung injury in humans [5]. Therefore, 
we wondered whether extracellular histones were able to damage human endothelial 
cells (HUVEC). We observed that cell viability, apoptosis, and cell morphology of 
HUVEC were gradually affected by histone concentration. Cell viability, measured by 
flow cytometry, decreased scarcely at 50 μg/mL but the decrease was more evident 
when cells were incubated with 100 μg/mL of histones (Figure 1A). The analysis of 
apoptosis by flow cytometry using Annexin-V-PE showed a significant increase in 
apoptotic cells at both 50 and 100 μg/mL (Figure 1B), as corroborated by fluorescence 
microscopy of cells using the same Annexin-V-PE staining; besides, there was a clear 
alteration of cell morphology and an increased number of dead cells (Figure 1C and 
1D, respectively).  
Autophagy is a cellular degradation process induced in response to many types of 
stress, but also a cellular mechanism used to promote cell survival, as cells defective in 
autophagy undergo apoptosis [25]. Thus, we wondered whether autophagy could be 
triggered after incubation with extracellular histones. To analyze the different steps of 
autophagy, assays were performed in the presence or absence of lysosomal inhibitors. 
As a marker of autophagy, we measured the LC3-II form, mammalian homolog of yeast 
Atg8 [26], which serves as an indicator of autophagosome formation progress. Western 
blot analysis showed an increase in the 16 KDa form of LC3 (LC3-II), indicating the 
activation of autophagy from 25 to 100 μg/mL of extracellular histones when using 
lysosomal inhibitors (Figure 2A). Immunofluorescence of LC3 (Figure 2B) further 
demonstrated the formation of autophagosomes in HUVEC exposed to extracellular 
histones.  
To clarify the specific concentration of extracellular histones that promotes the increase 
of lysosomal mass, we measured the levels of Lamp2 (Figure 3A). This protein is 
localized primarily in late endosomes and lysosomes [27] and acts as a receptor for the 
selective degradation of proteins in the lysosome [28]. Thus, Lamp2 is necessary for 
















autophagic process to form autophagolysosomes [25]. Our results show that Lamp2 
levels increased from 25 to 50 μg/mL of histones, being the highest expression at 100 
μg/mL (Figure 3A). Accordingly, the number of lysosomes, as indicated by lysotracker 
staining, increased in a dose-dependent manner from 25 to 100 μg/mL of histones 
(Figure 3B). These data support the notion that extracellular histones increase 
autophagosomes/autophagolysosomes formation in a dose-dependent manner. 
 
3.2. Extracellular histones activate autophagy by affecting different 
upstream mTOR regulators 
Since multiple upstream signals contribute to the activation of autophagy, we analyzed 
which specific pathways were activated in response to the stimulus produced by 
extracellular histones in HUVEC. 
The mammalian target of rapamycin (mTOR) is a serine/threonine protein kinase that 
negatively regulates autophagy [29, 30]. One of the upstream pathways involved in 
activation of mTOR-mediated autophagy is controlled by extracellular signal-regulated 
kinase 1/2 (ERK1/2) [31, 32], but we did not find any significant increase in the 
phosphorylation of ERK1/2 in response to extracellular histones (data not shown). 
Other upstream pathways involved in autophagy activation are mediated by Sestrin2, 
an inductor of LC3-II [31, 32]. Western blot analysis showed that expression of Sestrin2 
was increased according to the concentration of extracellular histones, showing highest 
expression at 50 and 100 μg/mL. Furthermore, we found an increase in the 
phosphorylation of Thr172 in AMPK (pho-AMPK) (see Figure 4A and 4B) that 
correlated with the increased levels of Sestrin2. AMPK is involved in processes that 
synergize to activate autophagy, both by direct activation of ULK1 and impairment of 
the mTOR-dependent inhibition of ULK1 [33]. In addition, the phosphorylation of AKT 
(Ser473) decreased inversely with the concentration of histones, which might result in 
blocking the activation of mTOR and thus activating autophagy [34] (Figure 4A and 
4B). Furthermore, a decrease in the phosphorylation of p70SK6 (a protein downstream 
to mTOR) at Thr389 was detected, suggesting again that autophagy is activated in 
HUVEC in response to a challenge of 25 to 100 g/mL of extracellular histones. Taken 
together, our results indicate that this increase in autophagy responds to an inhibition 
of mTOR-mediated pathways, as corroborated by the decrease in the phosphorylated 

















3.3. High concentrations of extracellular histones inversely affect the 
levels of pro- and anti-apoptotic proteins 
To study the relationship between apoptosis and autophagy, we evaluated the levels of 
the anti-apoptotic protein Bcl-2, the pro-apoptotic protein Bax, and the key regulator 
p53, which regulates both autophagy and apoptosis by either activating Sestrin2 or 
Bax, respectively [35]. We found that apoptosis was promoted by 50 and 100 μg/mL of 
extracellular histones, correlating with an increase Bax levels, and a decrease in Bcl-2 
levels (Figure 4C and 4D). It is known that phosphorylation of p53, among other 
factors, produces a p53-dependent up-regulation of Bax [36]. In our results, we found 
pho-p53/Bax-dependent activation of apoptosis at 100 μg/mL, which in turn may 
repress the expression of Bcl2 [37, 38]. Furthermore, the activation of Bax may be 
promoted by downregulation of Bcl-2, and it has been proposed that the Bax/Bcl2 ratio 
is critical to direct cells towards apoptosis [39, 40], accordingly to what we observe at 
50 and 100 μg/mL (Figure 4D) and again corroborating our results obtained by flow 
cytometry (Figure 1B).  
 
3.4. TLR2, TLR4 and TLR7/9 inhibitors modulate apoptosis and autophagy 
signals in HUVEC 
Since the role of histones regulating TLR-induced inflammation is not fully understood 
[41], we evaluated whether the use of TLR inhibitors (TLR2/TLR4 inhibitor OxPAPC 
(30µM), TLR7/TLR9 inhibitor iODN (0.7µM), and TLR4 inhibitor CLI-095 (3µM)) could 
affect the endothelial responses mediated by extracellular histones, either activating or 
inhibiting autophagy and apoptosis. We found increased percentage of apoptosis plus 
necrosis in HUVEC when cells were pre-incubated with TLR4 inhibitor (20.613.03) 
and TLR2/TLR4 inhibitor (22.568.08), but not when HUVEC were incubated with 
TLR7/TLR9 inhibitor, as compared to control conditions (10.444.29) (Figure 5A and 
Table 1). Using 50 µg/mL of extracellular histones the percentage of cells in apoptosis 
plus necrosis increased (30.173.04) when cells were pre-incubated with TLR4 
inhibitor and TLR2/TLR4 inhibitor (17.450.01) when compared to HUVEC incubated 
only with histones (16.634.45) (Figure 5A and Table 1). Finally, when cells were 
incubated at 100 µg/mL of extracellular histones, TLR4 inhibitor or TLR2/TLR4 inhibitor 
further increased apoptosis and necrosis (Figure 5A and Table 1). In this regard, when 
cells were incubated with 100 µg/mL of extracellular histones, the percentage of 
















inhibitor or TLR2/TLR4 inhibitor (45.386.58), as compared to HUVEC incubated only 
with 100 µg/mL of extracellular histones (21.933.27) (Figure 4A and Table 1). 
We also analysed cell apoptosis and necrosis produced by TLR inhibitors by 
comparing the effects of increasing histone concentrations. Results showed that 100 
µg/mL of extracellular histones significantly increase HUVEC apoptosis plus necrosis 
(comparing 100 µg/mL vs. 0 µg/mL and vs. 50 µg/mL) in HUVEC cells previously 
incubated with any of the TLR inhibitors (Table 2). These results also showed that 
TLR2/TLR4 inhibitor OXPAPC was the most cytotoxic TLR inhibitor in presence of 100 
µg/mL histones, whereas TLR4 inhibitor CLI-095 was the least cytotoxic (Table 1 and 
Table 2), which suggests that the inhibition of TLR2 can further compromise viability of 
HUVEC.  
When we analysed the effect of TLR inhibitors on autophagy by measuring the levels of 
LC3-II, we observed that OxPAPC, iODN and CLI-095 have the capacity to increase 
autophagy by themselves, and subsequent addition of extracellular histones did not 
produce any effect beyond that produced by TLR inhibitors (Figure 5B and Figure 5C). 
These results suggest that TLR inhibition, by itself, does not prevent autophagy 




The information regarding the mechanism by which endothelial cells die as a 
consequence of circulating histones - a process that occurs during a septic episode - is 
scarce. Histones have been detected in plasma of human patients with sepsis and 
septic shock reaching levels higher than 70 µg/mL [6, 17, 42]. Since several 
therapeutic strategies have failed in treating sepsis and septic shock [43], we consider 
relevant to characterize the mechanisms mediated by extracellular histones [20, 44].  
Extracellular histones can damage HUVEC through different histone-activated 
mechanisms which are dependent on the concentration of extracellular histones, as 
described by Abrams et al. after lung injury [5], and as we also observed in our 
experiments [19]. Here we show that histones induce different cellular responses that 
lead the cells towards activation of autophagy and/or apoptosis, depending on the 
concentration of extracellular histones. These pathways proceed through different 
mechanisms that regulate the balance between autophagy and apoptosis in relation to 
















Bax/Bcl-2 [45] and autophagy via sestrin2-driven pathways [35]. Autophagy has been 
described as a cell survival mechanism through suppression of apoptosis [46]. 
However, its key role as a stress signaling mechanism [47-49] makes autophagy a 
relevant process that can direct cells either to death or to survival. In fact, when 
autophagy is highly activated, it represents a pre-requisite for apoptosis and is related 
with programmed cell death in a non-apoptotic way [50]. The cross-regulation between 
cell survival, apoptosis and autophagy was evident in our studies, which showed that 
histones direct the cells to autophagy through Sestrin2 up-regulation and through a 
decrease in AKT activation. Histone concentrations above 25 µg/mL also promote 
phosphorylation of AMPK and dephosphorylation of p70S6K, contributing to autophagy 
upregulation. However, at concentrations of 50 µg/mL or higher, although autophagy 
was still activated, extracellular histones induced apoptosis in a p53-Bax-dependent 
manner. A representative scheme of the interlinkage between apoptotic and 
autophagic pathways affected by extracellular histones, as suggested by our 
experiments, is summarized in Figure 6. Our results, hence, reveal that the progress of 
endothelial cell death in response to extracellular histones depends on histones 
concentration, in a delicate balance between autophagy and apoptosis.  
These two mechanisms are closely related pathways [51]. Even the pro-survival 
functions of autophagy can produce deleterious effects that lead to cell death [52]. In 
addition, autophagy has been shown to be an important component of the innate 
immune response [53], in which Toll-like receptors (TLRs) are essential key 
contributors [54, 55]. Importantly, the endothelial autophagy system represents a novel 
immune regulatory mechanism that may be exploited therapeutically, in order to 
ameliorate the deleterious effects of deregulated autophagy and apoptosis in a variety 
of disorders in which levels of circulating histones are increased. However, histone 
concentrations above 50 µg/mL direct cells to apoptosis, which may produce 
endothelial activation that in turn may alter vascular homeostasis, as we have recently 
shown [19]. The development of TLR antagonists is of current interest for their 
application and potential use in therapy, being TLR4 and TLR2 the favourite targets for 
developing anti-sepsis drugs [56]. In fact, histones can bind to TLR2 and TLR4 [57], 
and more recently it has been proposed that histones produce upregulation of 
procoagulant tissue factor (TF), partly mediated by TLR2 and TLR4 [58]. However, 
some discrepancies have been found using these therapeutic approaches in mice and 
humans following the treatment of TLR inhibitors [56, 59]. Our results indicate that the 
use of TLR inhibitors increases apoptosis. Some reports suggested the role of 
















use of Eritoran, a TLR4-inhibitor, was able to decrease the expression of inflammatory 
cytokines and the inflammatory response, but it was unable to inhibit apoptosis in 
C57BL/6 mice during myocardial ischemia-reperfusion injury [60]. Furthermore, Ulbrich 
et al. reported that OxPAPC did not influence rotenone-induced apoptosis in SH-S5Y5, 
a human neuroblastoma cell line [61]. In other studies, Yvan-Charvet l. et al. showed 
the effect of OxPAPC activating macrophage apoptosis [62]. Importantly, the literature 
agrees with the multiple effects of OxPAPC on protective, inflammatory and pro-
apoptotic pathways, suggesting the multiple functions and mechanisms mediated by 
TLRs. Following this line of evidence, our results show that the concentration of 
circulating histones is relevant for the activation of cell death mechanisms in HUVEC, 
and that TLRs are important elements in the modulation of cell death responses. In this 
regard, the broad diversity of pathways mediated by TLRs suggests that besides their 
role in mediating anti-microbial defences, they can also induce apoptosis [63]. The 
synergistic effect we observed on apoptosis, when TLRs were inhibited before histone 
treatment, reinforces the idea of the importance of these receptors in mediating cell 
pro-survival by promoting autophagy. This fact is reinforced by results previously 
described by Wagner et al., in which TLR2 inhibition induces ERK1/2 and AKT 
signaling [64], which we know are relevant upstream pathways activating autophagy. 
Importantly, TLRs are involved in detection of PAMPs and microbes, initiating innate 
immune responses, and linking innate and adaptive immunity, as proposed by Takeda 
and Akira [65]. 
Our study shows that extracellular histones produce endothelial autophagy and cell 
apoptosis, which are dependent on the concentration of extracellular histones. 
Although further studies are required to thoroughly elucidate the effect of circulating 
histones on endothelial cells, our observations could have major implications for a 
variety of acute inflammatory disorders that are characterized by endothelial 
dysfunction, and that cause organ injury and failure, such as sepsis. In addition, we 
recently demonstrated that extracellular histones induce concentration-dependent 
changes in the two main vasoactive mediators, prostanoids and NO, resulting in a 
decrease in NO levels and a shift in prostanoids release [19], which is in agreement 
with the present results on Akt phosphorylation, since Akt activity positively correlates 
with NO generation in endothelial cells [66]. 
In addition to Akt, AMPK is a key gene controlling several cellular functions such as cell 
growth, sensor of cell energy and cell survival [67, 68]. Indeed, AMPK overexpression 
















AMPK activation can mediate mTOR inhibition [70] and, therefore, finally increasing 
autophagy in endothelial cells. 
The presence of circulating histones can be used as a biomarker to be considered 
during the evolution of a septic process [42] and could explain why TLRs inhibitors 
such as Eritoran have failed in clinical trials [59]. Furthermore, the effect observed 
using inhibitors of TLRs in which apoptosis is exacerbated when TLRs are inhibited, 
supports the clinical observations that toll-like receptor-2 (TLR2) polymorphisms are 
linked to increased risk of developing septic shock and increased mortality [71]. Our 
results agree with this hypothesis, because the inhibition of TLRs increased apoptosis 
in HUVEC when exposed to extracellular histones. Future studies might confirm 
whether any intervention in the autophagy pathway (activating or inhibiting) serves to 
modulate the pathogenic process of sepsis. This may provide novel therapeutic 
avenues for sepsis and septic shock, and harbours special relevance to avoid the 
pleiotropic effects of histones in endothelial cells and preventing the formation of a 
thrombotic environment [58]. 
 
5. Conclusions 
Histones have been detected in plasma of human patients with sepsis inducing 
different histone-activated mechanisms which are dependent on the concentration of 
these nuclear proteins. Histones produce damage to endothelial cells, thereby they 
may contribute to sepsis progression towards septic shock. Here we show that 
histones induce different cellular responses that commit the cell to autophagy and/or 
apoptosis. Furthermore, the results obtained demonstrate that the inhibition of TLRs 
increased apoptosis in HUVEC when cells were challenged with extracellular histones. 
Therefore, the results reveal the role of histones as new mediators participating in the 
control of autophagy and/or apoptosis, which could serve to improve survival in sepsis. 
In turn, histones may provide not only new biomarkers of sepsis-associated damage 
progression, as we demonstrated recently [42], but also novel therapeutic strategies to 
avoid the pleiotropic effects produced in endothelial cells, such as the increase of cell 
death and the formation of a thrombotic environment, among others. These results 
reinforce the necessity of developing combined multi-target therapeutic strategies that 

















 Conflict of Interest Statements 




Conception and study design: JLGG, CH, SN and FVP. Experiment performing and 
acquisition: JSIC, CA, JLGG, DPC, CBB, CRM, SN. Statistical analysis: EMGL. 
Drafting manuscript: JLGG, CRM, CA, SN, CH, and FVP. All authors approved the final 
version of manuscript. All authors agree to be accountable for all aspects of the work in 
ensuring that questions related to the accuracy or integrity of any part of the work are 
appropriately investigated and resolved. All persons designated as authors qualify for 
authorship, and all those who qualify for authorship are listed.  
 
Acknowledgements 
D.P-C. and J.S.I-C would like to thank “Atracció de Talent” fellowships from University 
of. Valencia.  Authors wish to thank S. Priego by her support performing the 




This work was supported by the INCLIVA Biomedical Research Institute and 
Generalitat Valenciana (grant number GV/2014/132) for the starting grants and 
AES2016 (ISCIII) grant number PI16/01036, co-financed by the European Regional 
Development Fund (ERDF) to J.L.G-G, the Grand Challenges Canada to F.V.P. J.L.G-
G, F.V.P and C.A would thank the Ministerio de Economía y Competitividad, Instituto 
de Salud Carlos III and the Center for Biomedical Network Research (CIBER of Rare 
Diseases; INGENIO2010). C.H. and S.N would thank the Ministerio de Economía y 
Competitividad, Instituto de Salud Carlos III - FEDER-ERDF (Red de Investigación 



















[1] J.G. Hirsch, Bactericidal action of histone, The Journal of experimental medicine, 108 (1958) 
925-944. 
[2] A.D. Pemberton, J.K. Brown, N.F. Inglis, Proteomic identification of interactions between 
histones and plasma proteins: implications for cytoprotection, Proteomics, 10 (2010) 1484-
1493. 
[3] R. Allam, C.R. Scherbaum, M.N. Darisipudi, S.R. Mulay, H. Hagele, J. Lichtnekert, J.H. 
Hagemann, K.V. Rupanagudi, M. Ryu, C. Schwarzenberger, B. Hohenstein, C. Hugo, B. Uhl, C.A. 
Reichel, F. Krombach, M. Monestier, H. Liapis, K. Moreth, L. Schaefer, H.J. Anders, Histones 
from dying renal cells aggravate kidney injury via TLR2 and TLR4, Journal of the American 
Society of Nephrology : JASN, 23 (2012) 1375-1388. 
[4] Z.G. Liu, S.Y. Ni, G.M. Chen, J. Cai, Z.H. Guo, P. Chang, Y.S. Li, Histones-mediated lymphocyte 
apoptosis during sepsis is dependent on p38 phosphorylation and mitochondrial permeability 
transition, PloS one, 8 (2013) e77131. 
[5] S.T. Abrams, N. Zhang, J. Manson, T. Liu, C. Dart, F. Baluwa, S.S. Wang, K. Brohi, A. Kipar, W. 
Yu, G. Wang, C.H. Toh, Circulating histones are mediators of trauma-associated lung injury, 
American journal of respiratory and critical care medicine, 187 (2013) 160-169. 
[6] J. Xu, X. Zhang, R. Pelayo, M. Monestier, C.T. Ammollo, F. Semeraro, F.B. Taylor, N.L. Esmon, 
F. Lupu, C.T. Esmon, Extracellular histones are major mediators of death in sepsis, Nature 
medicine, 15 (2009) 1318-1321. 
[7] M. Nakahara, T. Ito, K. Kawahara, M. Yamamoto, T. Nagasato, B. Shrestha, S. Yamada, T. 
Miyauchi, K. Higuchi, T. Takenaka, T. Yasuda, A. Matsunaga, Y. Kakihana, T. Hashiguchi, Y. 
Kanmura, I. Maruyama, Recombinant thrombomodulin protects mice against histone-induced 
lethal thromboembolism, PloS one, 8 (2013) e75961. 
[8] M.P. Fink, H.S. Warren, Strategies to improve drug development for sepsis, Nat Rev Drug 
Discov, 13 (2014) 741-758. 
[9] S. Khakpour, K. Wilhelmsen, J. Hellman, Vascular endothelial cell Toll-like receptor 
pathways in sepsis, Innate Immun, 21 (2015) 827-846. 
[10] R. Chen, R. Kang, X.G. Fan, D. Tang, Release and activity of histone in diseases, Cell death 
& disease, 5 (2014) e1370. 
[11] J. Xu, X. Zhang, M. Monestier, N.L. Esmon, C.T. Esmon, Extracellular histones are 
mediators of death through TLR2 and TLR4 in mouse fatal liver injury, J Immunol, 187 (2011) 
2626-2631. 
[12] C.G. McCarthy, S. Goulopoulou, C.F. Wenceslau, K. Spitler, T. Matsumoto, R.C. Webb, Toll-
like receptors and damage-associated molecular patterns: novel links between inflammation 
and hypertension, Am J Physiol Heart Circ Physiol, 306 (2014) H184-196. 
[13] G. Haraldsen, D. Kvale, B. Lien, I.N. Farstad, P. Brandtzaeg, Cytokine-regulated expression 
of E-selectin, intercellular adhesion molecule-1 (ICAM-1), and vascular cell adhesion molecule-
1 (VCAM-1) in human microvascular endothelial cells, Journal of immunology, 156 (1996) 
2558-2565. 
[14] T. Stefanec, Endothelial apoptosis: could it have a role in the pathogenesis and treatment 
of disease?, Chest, 117 (2000) 841-854. 
[15] Z. Mallat, A. Tedgui, Apoptosis in the vasculature: mechanisms and functional importance, 
British journal of pharmacology, 130 (2000) 947-962. 
[16] R.K. Winn, J.M. Harlan, The role of endothelial cell apoptosis in inflammatory and immune 
diseases, Journal of thrombosis and haemostasis : JTH, 3 (2005) 1815-1824. 
[17] T.A. Fuchs, A.A. Bhandari, D.D. Wagner, Histones induce rapid and profound 
















[18] T. Bombeli, A. Karsan, J.F. Tait, J.M. Harlan, Apoptotic vascular endothelial cells become 
procoagulant, Blood, 89 (1997) 2429-2442. 
[19] D. Perez-Cremades, C. Bueno-Beti, J.L. Garcia-Gimenez, J.S. Ibanez-Cabellos, C. 
Hermenegildo, F.V. Pallardo, S. Novella, Extracellular histones disarrange vasoactive mediators 
release through a COX-NOS interaction in human endothelial cells, J Cell Mol Med, (2017). 
[20] J.L.N. Garcia-Gimenez, S.  Carbonell, N.  Garcia-Simón, M. Blanquer, J. Hermenegildo, C.  
Pallardo, F.V., Recovering the enthusiasm for novel strategies to threat sepsis. [e-Letter], in:  
Blood, 2014, pp. http://blood/content/123/127/1098/reply - bloodjournal_el_8744; March 
1023, 2014. 
[21] E. Monsalve, P.J. Oviedo, M.A. Garcia-Perez, J.J. Tarin, A. Cano, C. Hermenegildo, Estradiol 
counteracts oxidized LDL-induced asymmetric dimethylarginine production by cultured human 
endothelial cells, Cardiovascular research, 73 (2007) 66-72. 
[22] D.C. Rubinsztein, A.M. Cuervo, B. Ravikumar, S. Sarkar, V. Korolchuk, S. Kaushik, D.J. 
Klionsky, In search of an "autophagomometer", Autophagy, 5 (2009) 585-589. 
[23] C.A. Schneider, W.S. Rasband, K.W. Eliceiri, NIH Image to ImageJ: 25 years of image 
analysis, Nat Methods, 9 (2012) 671-675. 
[24] C. Aguado, S. Sarkar, V.I. Korolchuk, O. Criado, S. Vernia, P. Boya, P. Sanz, S.R. de Cordoba, 
E. Knecht, D.C. Rubinsztein, Laforin, the most common protein mutated in Lafora disease, 
regulates autophagy, Hum Mol Genet, 19 (2010) 2867-2876. 
[25] B. Levine, G. Kroemer, Autophagy in the pathogenesis of disease, Cell, 132 (2008) 27-42. 
[26] N. Mizushima, T. Yoshimori, How to interpret LC3 immunoblotting, Autophagy, 3 (2007) 
542-545. 
[27] J. Lippincott-Schwartz, D.M. Fambrough, Cycling of the integral membrane glycoprotein, 
LEP100, between plasma membrane and lysosomes: kinetic and morphological analysis, Cell, 
49 (1987) 669-677. 
[28] A.M. Cuervo, J.F. Dice, A receptor for the selective uptake and degradation of proteins by 
lysosomes, Science, 273 (1996) 501-503. 
[29] C.H. Jung, S.H. Ro, J. Cao, N.M. Otto, D.H. Kim, mTOR regulation of autophagy, FEBS 
letters, 584 (2010) 1287-1295. 
[30] J.O. Pyo, J. Nah, Y.K. Jung, Molecules and their functions in autophagy, Experimental & 
molecular medicine, 44 (2012) 73-80. 
[31] M.C. Maiuri, S.A. Malik, E. Morselli, O. Kepp, A. Criollo, P.L. Mouchel, R. Carnuccio, G. 
Kroemer, Stimulation of autophagy by the p53 target gene Sestrin2, Cell cycle, 8 (2009) 1571-
1576. 
[32] M. Ishihara, M. Urushido, K. Hamada, T. Matsumoto, Y. Shimamura, K. Ogata, K. Inoue, Y. 
Taniguchi, T. Horino, M. Fujieda, S. Fujimoto, Y. Terada, Sestrin-2 and BNIP3 regulate 
autophagy and mitophagy in renal tubular cells in acute kidney injury, American journal of 
physiology. Renal physiology, 305 (2013) F495-509. 
[33] D.J. Klionsky, F.C. Abdalla, H. Abeliovich, R.T. Abraham, A. Acevedo-Arozena, K. Adeli, L. 
Agholme, M. Agnello, P. Agostinis, J.A. Aguirre-Ghiso, H.J. Ahn, O. Ait-Mohamed, S. Ait-Si-Ali, T. 
Akematsu, S. Akira, H.M. Al-Younes, M.A. Al-Zeer, M.L. Albert, R.L. Albin, J. Alegre-Abarrategui, 
M.F. Aleo, M. Alirezaei, A. Almasan, M. Almonte-Becerril, A. Amano, R. Amaravadi, S. 
Amarnath, A.O. Amer, N. Andrieu-Abadie, V. Anantharam, D.K. Ann, S. Anoopkumar-Dukie, H. 
Aoki, N. Apostolova, G. Arancia, J.P. Aris, K. Asanuma, N.Y. Asare, H. Ashida, V. Askanas, D.S. 
Askew, P. Auberger, M. Baba, S.K. Backues, E.H. Baehrecke, B.A. Bahr, X.Y. Bai, Y. Bailly, R. 
Baiocchi, G. Baldini, W. Balduini, A. Ballabio, B.A. Bamber, E.T. Bampton, G. Banhegyi, C.R. 
Bartholomew, D.C. Bassham, R.C. Bast, Jr., H. Batoko, B.H. Bay, I. Beau, D.M. Bechet, T.J. 
Begley, C. Behl, C. Behrends, S. Bekri, B. Bellaire, L.J. Bendall, L. Benetti, L. Berliocchi, H. 
Bernardi, F. Bernassola, S. Besteiro, I. Bhatia-Kissova, X. Bi, M. Biard-Piechaczyk, J.S. Blum, L.H. 
Boise, P. Bonaldo, D.L. Boone, B.C. Bornhauser, K.R. Bortoluci, I. Bossis, F. Bost, J.P. Bourquin, 
P. Boya, M. Boyer-Guittaut, P.V. Bozhkov, N.R. Brady, C. Brancolini, A. Brech, J.E. Brenman, A. 
















Brumell, N. Brunetti-Pierri, U.T. Brunk, D.E. Bulman, S.J. Bultman, G. Bultynck, L.F. Burbulla, W. 
Bursch, J.P. Butchar, W. Buzgariu, S.P. Bydlowski, K. Cadwell, M. Cahova, D. Cai, J. Cai, Q. Cai, B. 
Calabretta, J. Calvo-Garrido, N. Camougrand, M. Campanella, J. Campos-Salinas, E. Candi, L. 
Cao, A.B. Caplan, S.R. Carding, S.M. Cardoso, J.S. Carew, C.R. Carlin, V. Carmignac, L.A. 
Carneiro, S. Carra, R.A. Caruso, G. Casari, C. Casas, R. Castino, E. Cebollero, F. Cecconi, J. Celli, 
H. Chaachouay, H.J. Chae, C.Y. Chai, D.C. Chan, E.Y. Chan, R.C. Chang, C.M. Che, C.C. Chen, G.C. 
Chen, G.Q. Chen, M. Chen, Q. Chen, S.S. Chen, W. Chen, X. Chen, X. Chen, X. Chen, Y.G. Chen, 
Y. Chen, Y. Chen, Y.J. Chen, Z. Chen, A. Cheng, C.H. Cheng, Y. Cheng, H. Cheong, J.H. Cheong, S. 
Cherry, R. Chess-Williams, Z.H. Cheung, E. Chevet, H.L. Chiang, R. Chiarelli, T. Chiba, L.S. Chin, 
S.H. Chiou, F.V. Chisari, C.H. Cho, D.H. Cho, A.M. Choi, D. Choi, K.S. Choi, M.E. Choi, S. Chouaib, 
D. Choubey, V. Choubey, C.T. Chu, T.H. Chuang, S.H. Chueh, T. Chun, Y.J. Chwae, M.L. Chye, R. 
Ciarcia, M.R. Ciriolo, M.J. Clague, R.S. Clark, P.G. Clarke, R. Clarke, P. Codogno, H.A. Coller, M.I. 
Colombo, S. Comincini, M. Condello, F. Condorelli, M.R. Cookson, G.H. Coombs, I. Coppens, R. 
Corbalan, P. Cossart, P. Costelli, S. Costes, A. Coto-Montes, E. Couve, F.P. Coxon, J.M. Cregg, 
J.L. Crespo, M.J. Cronje, A.M. Cuervo, J.J. Cullen, M.J. Czaja, M. D'Amelio, A. Darfeuille-
Michaud, L.M. Davids, F.E. Davies, M. De Felici, J.F. de Groot, C.A. de Haan, L. De Martino, A. 
De Milito, V. De Tata, J. Debnath, A. Degterev, B. Dehay, L.M. Delbridge, F. Demarchi, Y.Z. 
Deng, J. Dengjel, P. Dent, D. Denton, V. Deretic, S.D. Desai, R.J. Devenish, M. Di Gioacchino, G. 
Di Paolo, C. Di Pietro, G. Diaz-Araya, I. Diaz-Laviada, M.T. Diaz-Meco, J. Diaz-Nido, I. Dikic, S.P. 
Dinesh-Kumar, W.X. Ding, C.W. Distelhorst, A. Diwan, M. Djavaheri-Mergny, S. Dokudovskaya, 
Z. Dong, F.C. Dorsey, V. Dosenko, J.J. Dowling, S. Doxsey, M. Dreux, M.E. Drew, Q. Duan, M.A. 
Duchosal, K. Duff, I. Dugail, M. Durbeej, M. Duszenko, C.L. Edelstein, A.L. Edinger, G. Egea, L. 
Eichinger, N.T. Eissa, S. Ekmekcioglu, W.S. El-Deiry, Z. Elazar, M. Elgendy, L.M. Ellerby, K.E. Eng, 
A.M. Engelbrecht, S. Engelender, J. Erenpreisa, R. Escalante, A. Esclatine, E.L. Eskelinen, L. 
Espert, V. Espina, H. Fan, J. Fan, Q.W. Fan, Z. Fan, S. Fang, Y. Fang, M. Fanto, A. Fanzani, T. 
Farkas, J.C. Farre, M. Faure, M. Fechheimer, C.G. Feng, J. Feng, Q. Feng, Y. Feng, L. Fesus, R. 
Feuer, M.E. Figueiredo-Pereira, G.M. Fimia, D.C. Fingar, S. Finkbeiner, T. Finkel, K.D. Finley, F. 
Fiorito, E.A. Fisher, P.B. Fisher, M. Flajolet, M.L. Florez-McClure, S. Florio, E.A. Fon, F. Fornai, F. 
Fortunato, R. Fotedar, D.H. Fowler, H.S. Fox, R. Franco, L.B. Frankel, M. Fransen, J.M. Fuentes, 
J. Fueyo, J. Fujii, K. Fujisaki, E. Fujita, M. Fukuda, R.H. Furukawa, M. Gaestel, P. Gailly, M. 
Gajewska, B. Galliot, V. Galy, S. Ganesh, B. Ganetzky, I.G. Ganley, F.B. Gao, G.F. Gao, J. Gao, L. 
Garcia, G. Garcia-Manero, M. Garcia-Marcos, M. Garmyn, A.L. Gartel, E. Gatti, M. Gautel, T.R. 
Gawriluk, M.E. Gegg, J. Geng, M. Germain, J.E. Gestwicki, D.A. Gewirtz, S. Ghavami, P. Ghosh, 
A.M. Giammarioli, A.N. Giatromanolaki, S.B. Gibson, R.W. Gilkerson, M.L. Ginger, H.N. 
Ginsberg, J. Golab, M.S. Goligorsky, P. Golstein, C. Gomez-Manzano, E. Goncu, C. Gongora, C.D. 
Gonzalez, R. Gonzalez, C. Gonzalez-Estevez, R.A. Gonzalez-Polo, E. Gonzalez-Rey, N.V. 
Gorbunov, S. Gorski, S. Goruppi, R.A. Gottlieb, D. Gozuacik, G.E. Granato, G.D. Grant, K.N. 
Green, A. Gregorc, F. Gros, C. Grose, T.W. Grunt, P. Gual, J.L. Guan, K.L. Guan, S.M. Guichard, 
A.S. Gukovskaya, I. Gukovsky, J. Gunst, A.B. Gustafsson, A.J. Halayko, A.N. Hale, S.K. Halonen, 
M. Hamasaki, F. Han, T. Han, M.K. Hancock, M. Hansen, H. Harada, M. Harada, S.E. Hardt, J.W. 
Harper, A.L. Harris, J. Harris, S.D. Harris, M. Hashimoto, J.A. Haspel, S. Hayashi, L.A. Hazelhurst, 
C. He, Y.W. He, M.J. Hebert, K.A. Heidenreich, M.H. Helfrich, G.V. Helgason, E.P. Henske, B. 
Herman, P.K. Herman, C. Hetz, S. Hilfiker, J.A. Hill, L.J. Hocking, P. Hofman, T.G. Hofmann, J. 
Hohfeld, T.L. Holyoake, M.H. Hong, D.A. Hood, G.S. Hotamisligil, E.J. Houwerzijl, M. Hoyer-
Hansen, B. Hu, C.A. Hu, H.M. Hu, Y. Hua, C. Huang, J. Huang, S. Huang, W.P. Huang, T.B. Huber, 
W.K. Huh, T.H. Hung, T.R. Hupp, G.M. Hur, J.B. Hurley, S.N. Hussain, P.J. Hussey, J.J. Hwang, S. 
Hwang, A. Ichihara, S. Ilkhanizadeh, K. Inoki, T. Into, V. Iovane, J.L. Iovanna, N.Y. Ip, Y. Isaka, H. 
Ishida, C. Isidoro, K. Isobe, A. Iwasaki, M. Izquierdo, Y. Izumi, P.M. Jaakkola, M. Jaattela, G.R. 
Jackson, W.T. Jackson, B. Janji, M. Jendrach, J.H. Jeon, E.B. Jeung, H. Jiang, H. Jiang, J.X. Jiang, 
M. Jiang, Q. Jiang, X. Jiang, X. Jiang, A. Jimenez, M. Jin, S. Jin, C.O. Joe, T. Johansen, D.E. 
Johnson, G.V. Johnson, N.L. Jones, B. Joseph, S.K. Joseph, A.M. Joubert, G. Juhasz, L. Juillerat-
















Kamada, V.O. Kaminskyy, H.H. Kampinga, H. Kanamori, C. Kang, K.B. Kang, K.I. Kang, R. Kang, 
Y.A. Kang, T. Kanki, T.D. Kanneganti, H. Kanno, A.G. Kanthasamy, A. Kanthasamy, V. Karantza, 
G.P. Kaushal, S. Kaushik, Y. Kawazoe, P.Y. Ke, J.H. Kehrl, A. Kelekar, C. Kerkhoff, D.H. Kessel, H. 
Khalil, J.A. Kiel, A.A. Kiger, A. Kihara, D.R. Kim, D.H. Kim, D.H. Kim, E.K. Kim, H.R. Kim, J.S. Kim, 
J.H. Kim, J.C. Kim, J.K. Kim, P.K. Kim, S.W. Kim, Y.S. Kim, Y. Kim, A. Kimchi, A.C. Kimmelman, J.S. 
King, T.J. Kinsella, V. Kirkin, L.A. Kirshenbaum, K. Kitamoto, K. Kitazato, L. Klein, W.T. Klimecki, J. 
Klucken, E. Knecht, B.C. Ko, J.C. Koch, H. Koga, J.Y. Koh, Y.H. Koh, M. Koike, M. Komatsu, E. 
Kominami, H.J. Kong, W.J. Kong, V.I. Korolchuk, Y. Kotake, M.I. Koukourakis, J.B. Kouri Flores, 
A.L. Kovacs, C. Kraft, D. Krainc, H. Kramer, C. Kretz-Remy, A.M. Krichevsky, G. Kroemer, R. 
Kruger, O. Krut, N.T. Ktistakis, C.Y. Kuan, R. Kucharczyk, A. Kumar, R. Kumar, S. Kumar, M. 
Kundu, H.J. Kung, T. Kurz, H.J. Kwon, A.R. La Spada, F. Lafont, T. Lamark, J. Landry, J.D. Lane, P. 
Lapaquette, J.F. Laporte, L. Laszlo, S. Lavandero, J.N. Lavoie, R. Layfield, P.A. Lazo, W. Le, L. Le 
Cam, D.J. Ledbetter, A.J. Lee, B.W. Lee, G.M. Lee, J. Lee, J.H. Lee, M. Lee, M.S. Lee, S.H. Lee, C. 
Leeuwenburgh, P. Legembre, R. Legouis, M. Lehmann, H.Y. Lei, Q.Y. Lei, D.A. Leib, J. Leiro, J.J. 
Lemasters, A. Lemoine, M.S. Lesniak, D. Lev, V.V. Levenson, B. Levine, E. Levy, F. Li, J.L. Li, L. Li, 
S. Li, W. Li, X.J. Li, Y.B. Li, Y.P. Li, C. Liang, Q. Liang, Y.F. Liao, P.P. Liberski, A. Lieberman, H.J. 
Lim, K.L. Lim, K. Lim, C.F. Lin, F.C. Lin, J. Lin, J.D. Lin, K. Lin, W.W. Lin, W.C. Lin, Y.L. Lin, R. 
Linden, P. Lingor, J. Lippincott-Schwartz, M.P. Lisanti, P.B. Liton, B. Liu, C.F. Liu, K. Liu, L. Liu, 
Q.A. Liu, W. Liu, Y.C. Liu, Y. Liu, R.A. Lockshin, C.N. Lok, S. Lonial, B. Loos, G. Lopez-Berestein, C. 
Lopez-Otin, L. Lossi, M.T. Lotze, P. Low, B. Lu, B. Lu, B. Lu, Z. Lu, F. Luciano, N.W. Lukacs, A.H. 
Lund, M.A. Lynch-Day, Y. Ma, F. Macian, J.P. MacKeigan, K.F. Macleod, F. Madeo, L. Maiuri, 
M.C. Maiuri, D. Malagoli, M.C. Malicdan, W. Malorni, N. Man, E.M. Mandelkow, S. Manon, I. 
Manov, K. Mao, X. Mao, Z. Mao, P. Marambaud, D. Marazziti, Y.L. Marcel, K. Marchbank, P. 
Marchetti, S.J. Marciniak, M. Marcondes, M. Mardi, G. Marfe, G. Marino, M. Markaki, M.R. 
Marten, S.J. Martin, C. Martinand-Mari, W. Martinet, M. Martinez-Vicente, M. Masini, P. 
Matarrese, S. Matsuo, R. Matteoni, A. Mayer, N.M. Mazure, D.J. McConkey, M.J. McConnell, C. 
McDermott, C. McDonald, G.M. McInerney, S.L. McKenna, B. McLaughlin, P.J. McLean, C.R. 
McMaster, G.A. McQuibban, A.J. Meijer, M.H. Meisler, A. Melendez, T.J. Melia, G. Melino, M.A. 
Mena, J.A. Menendez, R.F. Menna-Barreto, M.B. Menon, F.M. Menzies, C.A. Mercer, A. 
Merighi, D.E. Merry, S. Meschini, C.G. Meyer, T.F. Meyer, C.Y. Miao, J.Y. Miao, P.A. Michels, C. 
Michiels, D. Mijaljica, A. Milojkovic, S. Minucci, C. Miracco, C.K. Miranti, I. Mitroulis, K. 
Miyazawa, N. Mizushima, B. Mograbi, S. Mohseni, X. Molero, B. Mollereau, F. Mollinedo, T. 
Momoi, I. Monastyrska, M.M. Monick, M.J. Monteiro, M.N. Moore, R. Mora, K. Moreau, P.I. 
Moreira, Y. Moriyasu, J. Moscat, S. Mostowy, J.C. Mottram, T. Motyl, C.E. Moussa, S. Muller, S. 
Muller, K. Munger, C. Munz, L.O. Murphy, M.E. Murphy, A. Musaro, I. Mysorekar, E. Nagata, K. 
Nagata, A. Nahimana, U. Nair, T. Nakagawa, K. Nakahira, H. Nakano, H. Nakatogawa, M. 
Nanjundan, N.I. Naqvi, D.P. Narendra, M. Narita, M. Navarro, S.T. Nawrocki, T.Y. Nazarko, A. 
Nemchenko, M.G. Netea, T.P. Neufeld, P.A. Ney, I.P. Nezis, H.P. Nguyen, D. Nie, I. Nishino, C. 
Nislow, R.A. Nixon, T. Noda, A.A. Noegel, A. Nogalska, S. Noguchi, L. Notterpek, I. Novak, T. 
Nozaki, N. Nukina, T. Nurnberger, B. Nyfeler, K. Obara, T.D. Oberley, S. Oddo, M. Ogawa, T. 
Ohashi, K. Okamoto, N.L. Oleinick, F.J. Oliver, L.J. Olsen, S. Olsson, O. Opota, T.F. Osborne, G.K. 
Ostrander, K. Otsu, J.H. Ou, M. Ouimet, M. Overholtzer, B. Ozpolat, P. Paganetti, U. Pagnini, N. 
Pallet, G.E. Palmer, C. Palumbo, T. Pan, T. Panaretakis, U.B. Pandey, Z. Papackova, I. 
Papassideri, I. Paris, J. Park, O.K. Park, J.B. Parys, K.R. Parzych, S. Patschan, C. Patterson, S. 
Pattingre, J.M. Pawelek, J. Peng, D.H. Perlmutter, I. Perrotta, G. Perry, S. Pervaiz, M. Peter, G.J. 
Peters, M. Petersen, G. Petrovski, J.M. Phang, M. Piacentini, P. Pierre, V. Pierrefite-Carle, G. 
Pierron, R. Pinkas-Kramarski, A. Piras, N. Piri, L.C. Platanias, S. Poggeler, M. Poirot, A. Poletti, C. 
Pous, M. Pozuelo-Rubio, M. Praetorius-Ibba, A. Prasad, M. Prescott, M. Priault, N. Produit-
Zengaffinen, A. Progulske-Fox, T. Proikas-Cezanne, S. Przedborski, K. Przyklenk, R. Puertollano, 
J. Puyal, S.B. Qian, L. Qin, Z.H. Qin, S.E. Quaggin, N. Raben, H. Rabinowich, S.W. Rabkin, I. 
Rahman, A. Rami, G. Ramm, G. Randall, F. Randow, V.A. Rao, J.C. Rathmell, B. Ravikumar, S.K. 
















Reiter, J. Ren, J.L. Revuelta, C.J. Rhodes, K. Ritis, E. Rizzo, J. Robbins, M. Roberge, H. Roca, M.C. 
Roccheri, S. Rocchi, H.P. Rodemann, S. Rodriguez de Cordoba, B. Rohrer, I.B. Roninson, K. 
Rosen, M.M. Rost-Roszkowska, M. Rouis, K.M. Rouschop, F. Rovetta, B.P. Rubin, D.C. 
Rubinsztein, K. Ruckdeschel, E.B. Rucker, 3rd, A. Rudich, E. Rudolf, N. Ruiz-Opazo, R. Russo, T.E. 
Rusten, K.M. Ryan, S.W. Ryter, D.M. Sabatini, J. Sadoshima, T. Saha, T. Saitoh, H. Sakagami, Y. 
Sakai, G.H. Salekdeh, P. Salomoni, P.M. Salvaterra, G. Salvesen, R. Salvioli, A.M. Sanchez, J.A. 
Sanchez-Alcazar, R. Sanchez-Prieto, M. Sandri, U. Sankar, P. Sansanwal, L. Santambrogio, S. 
Saran, S. Sarkar, M. Sarwal, C. Sasakawa, A. Sasnauskiene, M. Sass, K. Sato, M. Sato, A.H. 
Schapira, M. Scharl, H.M. Schatzl, W. Scheper, S. Schiaffino, C. Schneider, M.E. Schneider, R. 
Schneider-Stock, P.V. Schoenlein, D.F. Schorderet, C. Schuller, G.K. Schwartz, L. Scorrano, L. 
Sealy, P.O. Seglen, J. Segura-Aguilar, I. Seiliez, O. Seleverstov, C. Sell, J.B. Seo, D. Separovic, V. 
Setaluri, T. Setoguchi, C. Settembre, J.J. Shacka, M. Shanmugam, I.M. Shapiro, E. Shaulian, R.J. 
Shaw, J.H. Shelhamer, H.M. Shen, W.C. Shen, Z.H. Sheng, Y. Shi, K. Shibuya, Y. Shidoji, J.J. Shieh, 
C.M. Shih, Y. Shimada, S. Shimizu, T. Shintani, O.S. Shirihai, G.C. Shore, A.A. Sibirny, S.B. Sidhu, 
B. Sikorska, E.C. Silva-Zacarin, A. Simmons, A.K. Simon, H.U. Simon, C. Simone, A. Simonsen, 
D.A. Sinclair, R. Singh, D. Sinha, F.A. Sinicrope, A. Sirko, P.M. Siu, E. Sivridis, V. Skop, V.P. 
Skulachev, R.S. Slack, S.S. Smaili, D.R. Smith, M.S. Soengas, T. Soldati, X. Song, A.K. Sood, T.W. 
Soong, F. Sotgia, S.A. Spector, C.D. Spies, W. Springer, S.M. Srinivasula, L. Stefanis, J.S. Steffan, 
R. Stendel, H. Stenmark, A. Stephanou, S.T. Stern, C. Sternberg, B. Stork, P. Stralfors, C.S. 
Subauste, X. Sui, D. Sulzer, J. Sun, S.Y. Sun, Z.J. Sun, J.J. Sung, K. Suzuki, T. Suzuki, M.S. 
Swanson, C. Swanton, S.T. Sweeney, L.K. Sy, G. Szabadkai, I. Tabas, H. Taegtmeyer, M. Tafani, 
K. Takacs-Vellai, Y. Takano, K. Takegawa, G. Takemura, F. Takeshita, N.J. Talbot, K.S. Tan, K. 
Tanaka, K. Tanaka, D. Tang, D. Tang, I. Tanida, B.A. Tannous, N. Tavernarakis, G.S. Taylor, G.A. 
Taylor, J.P. Taylor, L.S. Terada, A. Terman, G. Tettamanti, K. Thevissen, C.B. Thompson, A. 
Thorburn, M. Thumm, F. Tian, Y. Tian, G. Tocchini-Valentini, A.M. Tolkovsky, Y. Tomino, L. 
Tonges, S.A. Tooze, C. Tournier, J. Tower, R. Towns, V. Trajkovic, L.H. Travassos, T.F. Tsai, M.P. 
Tschan, T. Tsubata, A. Tsung, B. Turk, L.S. Turner, S.C. Tyagi, Y. Uchiyama, T. Ueno, M. 
Umekawa, R. Umemiya-Shirafuji, V.K. Unni, M.I. Vaccaro, E.M. Valente, G. Van den Berghe, I.J. 
van der Klei, W. van Doorn, L.F. van Dyk, M. van Egmond, L.A. van Grunsven, P. Vandenabeele, 
W.P. Vandenberghe, I. Vanhorebeek, E.C. Vaquero, G. Velasco, T. Vellai, J.M. Vicencio, R.D. 
Vierstra, M. Vila, C. Vindis, G. Viola, M.T. Viscomi, O.V. Voitsekhovskaja, C. von Haefen, M. 
Votruba, K. Wada, R. Wade-Martins, C.L. Walker, C.M. Walsh, J. Walter, X.B. Wan, A. Wang, C. 
Wang, D. Wang, F. Wang, F. Wang, G. Wang, H. Wang, H.G. Wang, H.D. Wang, J. Wang, K. 
Wang, M. Wang, R.C. Wang, X. Wang, X. Wang, Y.J. Wang, Y. Wang, Z. Wang, Z.C. Wang, Z. 
Wang, D.G. Wansink, D.M. Ward, H. Watada, S.L. Waters, P. Webster, L. Wei, C.C. Weihl, W.A. 
Weiss, S.M. Welford, L.P. Wen, C.A. Whitehouse, J.L. Whitton, A.J. Whitworth, T. Wileman, 
J.W. Wiley, S. Wilkinson, D. Willbold, R.L. Williams, P.R. Williamson, B.G. Wouters, C. Wu, D.C. 
Wu, W.K. Wu, A. Wyttenbach, R.J. Xavier, Z. Xi, P. Xia, G. Xiao, Z. Xie, Z. Xie, D.Z. Xu, J. Xu, L. Xu, 
X. Xu, A. Yamamoto, A. Yamamoto, S. Yamashina, M. Yamashita, X. Yan, M. Yanagida, D.S. 
Yang, E. Yang, J.M. Yang, S.Y. Yang, W. Yang, W.Y. Yang, Z. Yang, M.C. Yao, T.P. Yao, B. Yeganeh, 
W.L. Yen, J.J. Yin, X.M. Yin, O.J. Yoo, G. Yoon, S.Y. Yoon, T. Yorimitsu, Y. Yoshikawa, T. 
Yoshimori, K. Yoshimoto, H.J. You, R.J. Youle, A. Younes, L. Yu, L. Yu, S.W. Yu, W.H. Yu, Z.M. 
Yuan, Z. Yue, C.H. Yun, M. Yuzaki, O. Zabirnyk, E. Silva-Zacarin, D. Zacks, E. Zacksenhaus, N. 
Zaffaroni, Z. Zakeri, H.J. Zeh, 3rd, S.O. Zeitlin, H. Zhang, H.L. Zhang, J. Zhang, J.P. Zhang, L. 
Zhang, L. Zhang, M.Y. Zhang, X.D. Zhang, M. Zhao, Y.F. Zhao, Y. Zhao, Z.J. Zhao, X. Zheng, B. 
Zhivotovsky, Q. Zhong, C.Z. Zhou, C. Zhu, W.G. Zhu, X.F. Zhu, X. Zhu, Y. Zhu, T. Zoladek, W.X. 
Zong, A. Zorzano, J. Zschocke, B. Zuckerbraun, Guidelines for the use and interpretation of 
assays for monitoring autophagy, Autophagy, 8 (2012) 445-544. 
[34] S. Arico, A. Petiot, C. Bauvy, P.F. Dubbelhuis, A.J. Meijer, P. Codogno, E. Ogier-Denis, The 
tumor suppressor PTEN positively regulates macroautophagy by inhibiting the 
phosphatidylinositol 3-kinase/protein kinase B pathway, The Journal of biological chemistry, 
















[35] A.V. Budanov, M. Karin, p53 target genes sestrin1 and sestrin2 connect genotoxic stress 
and mTOR signaling, Cell, 134 (2008) 451-460. 
[36] M. Castedo, T. Roumier, J. Blanco, K.F. Ferri, J. Barretina, L.A. Tintignac, K. Andreau, J.L. 
Perfettini, A. Amendola, R. Nardacci, P. Leduc, D.E. Ingber, S. Druillennec, B. Roques, S.A. 
Leibovitch, M. Vilella-Bach, J. Chen, J.A. Este, N. Modjtahedi, M. Piacentini, G. Kroemer, 
Sequential involvement of Cdk1, mTOR and p53 in apoptosis induced by the HIV-1 envelope, 
The EMBO journal, 21 (2002) 4070-4080. 
[37] Y. Wu, J.W. Mehew, C.A. Heckman, M. Arcinas, L.M. Boxer, Negative regulation of bcl-2 
expression by p53 in hematopoietic cells, Oncogene, 20 (2001) 240-251. 
[38] T. Miyashita, S. Krajewski, M. Krajewska, H.G. Wang, H.K. Lin, D.A. Liebermann, B. 
Hoffman, J.C. Reed, Tumor suppressor p53 is a regulator of bcl-2 and bax gene expression in 
vitro and in vivo, Oncogene, 9 (1994) 1799-1805. 
[39] H. Perlman, X. Zhang, M.W. Chen, K. Walsh, R. Buttyan, An elevated bax/bcl-2 ratio 
corresponds with the onset of prostate epithelial cell apoptosis, Cell Death Differ, 6 (1999) 48-
54. 
[40] S. Salakou, D. Kardamakis, A.C. Tsamandas, V. Zolota, E. Apostolakis, V. Tzelepi, P. 
Papathanasopoulos, D.S. Bonikos, T. Papapetropoulos, T. Petsas, D. Dougenis, Increased 
Bax/Bcl-2 ratio up-regulates caspase-3 and increases apoptosis in the thymus of patients with 
myasthenia gravis, In Vivo, 21 (2007) 123-132. 
[41] W. Wang, M. Deng, X. Liu, W. Ai, Q. Tang, J. Hu, TLR4 activation induces nontolerant 
inflammatory response in endothelial cells, Inflammation, 34 (2011) 509-518. 
[42] J.L. Garcia-Gimenez, C. Roma-Mateo, N. Carbonell, L. Palacios, L. Peiro-Chova, E. Garcia-
Lopez, M. Garcia-Simon, R. Lahuerta, C. Gimenez-Garzo, E. Berenguer-Pascual, M.I. Mora, M.L. 
Valero, A. Alpizar, F.J. Corrales, J. Blanquer, F.V. Pallardo, A new mass spectrometry-based 
method for the quantification of histones in plasma from septic shock patients, Sci Rep, 7 
(2017) 10643. 
[43] J.C. Marshall, Why have clinical trials in sepsis failed?, Trends in molecular medicine, 20 
(2014) 195-203. 
[44] J.L. García-Giménez, C. Romá-Mateo, M. Seco-Cervera, J.S. Ibañez-Cabellos, F.V. Pallardó, 
Chapter 25 - Circulating Histones and Nucleosomes as Biomarkers in Sepsis and Septic Shock 
A2 - García-Giménez, José Luis, in:  Epigenetic Biomarkers and Diagnostics, Academic Press, 
Boston, 2016, pp. 497-517. 
[45] M.T. Hemann, S.W. Lowe, The p53-Bcl-2 connection, Cell death and differentiation, 13 
(2006) 1256-1259. 
[46] B.A. Ballif, J. Blenis, Molecular mechanisms mediating mammalian mitogen-activated 
protein kinase (MAPK) kinase (MEK)-MAPK cell survival signals, Cell Growth Differ, 12 (2001) 
397-408. 
[47] G. Kroemer, G. Marino, B. Levine, Autophagy and the integrated stress response, Mol Cell, 
40 (2010) 280-293. 
[48] L. Murrow, J. Debnath, Autophagy as a stress-response and quality-control mechanism: 
implications for cell injury and human disease, Annu Rev Pathol, 8 (2013) 105-137. 
[49] P. Ravanan, I.F. Srikumar, P. Talwar, Autophagy: The spotlight for cellular stress responses, 
Life Sci, 188 (2017) 53-67. 
[50] S. Shimizu, T. Kanaseki, N. Mizushima, T. Mizuta, S. Arakawa-Kobayashi, C.B. Thompson, Y. 
Tsujimoto, Role of Bcl-2 family proteins in a non-apoptotic programmed cell death dependent 
on autophagy genes, Nat Cell Biol, 6 (2004) 1221-1228. 
[51] A. Trocoli, M. Djavaheri-Mergny, The complex interplay between autophagy and NF-
kappaB signaling pathways in cancer cells, American journal of cancer research, 1 (2011) 629-
649. 
[52] R. Kang, H.J. Zeh, M.T. Lotze, D. Tang, The Beclin 1 network regulates autophagy and 
















[53] K. Kirkegaard, M.P. Taylor, W.T. Jackson, Cellular autophagy: surrender, avoidance and 
subversion by microorganisms, Nature reviews. Microbiology, 2 (2004) 301-314. 
[54] Y. Xu, C. Jagannath, X.D. Liu, A. Sharafkhaneh, K.E. Kolodziejska, N.T. Eissa, Toll-like 
receptor 4 is a sensor for autophagy associated with innate immunity, Immunity, 27 (2007) 
135-144. 
[55] M.A. Delgado, R.A. Elmaoued, A.S. Davis, G. Kyei, V. Deretic, Toll-like receptors control 
autophagy, The EMBO journal, 27 (2008) 1110-1121. 
[56] A. Savva, T. Roger, Targeting toll-like receptors: promising therapeutic strategies for the 
management of sepsis-associated pathology and infectious diseases, Frontiers in immunology, 
4 (2013) 387. 
[57] R. Allam, S.V. Kumar, M.N. Darisipudi, H.J. Anders, Extracellular histones in tissue injury 
and inflammation, Journal of molecular medicine, 92 (2014) 465-472. 
[58] J.E. Kim, H.J. Yoo, J.Y. Gu, H.K. Kim, Histones Induce the Procoagulant Phenotype of 
Endothelial Cells through Tissue Factor Up-Regulation and Thrombomodulin Down-Regulation, 
PloS one, 11 (2016) e0156763. 
[59] S.M. Opal, P.F. Laterre, B. Francois, S.P. LaRosa, D.C. Angus, J.P. Mira, X. Wittebole, T. 
Dugernier, D. Perrotin, M. Tidswell, L. Jauregui, K. Krell, J. Pachl, T. Takahashi, C. Peckelsen, E. 
Cordasco, C.S. Chang, S. Oeyen, N. Aikawa, T. Maruyama, R. Schein, A.C. Kalil, M. Van Nuffelen, 
M. Lynn, D.P. Rossignol, J. Gogate, M.B. Roberts, J.L. Wheeler, J.L. Vincent, A.S. Group, Effect of 
eritoran, an antagonist of MD2-TLR4, on mortality in patients with severe sepsis: the ACCESS 
randomized trial, Jama, 309 (2013) 1154-1162. 
[60] A. Shimamoto, A.J. Chong, M. Yada, S. Shomura, H. Takayama, A.J. Fleisig, M.L. Agnew, 
C.R. Hampton, C.L. Rothnie, D.J. Spring, T.H. Pohlman, H. Shimpo, E.D. Verrier, Inhibition of 
Toll-like receptor 4 with eritoran attenuates myocardial ischemia-reperfusion injury, 
Circulation, 114 (2006) I270-274. 
[61] F. Ulbrich, K. Kaufmann, M. Roesslein, F. Wellner, V. Auwarter, J. Kempf, T. Loop, H. 
Buerkle, U. Goebel, Argon Mediates Anti-Apoptotic Signaling and Neuroprotection via 
Inhibition of Toll-Like Receptor 2 and 4, PloS one, 10 (2015) e0143887. 
[62] L. Yvan-Charvet, T.A. Pagler, T.A. Seimon, E. Thorp, C.L. Welch, J.L. Witztum, I. Tabas, A.R. 
Tall, ABCA1 and ABCG1 protect against oxidative stress-induced macrophage apoptosis during 
efferocytosis, Circulation research, 106 (2010) 1861-1869. 
[63] B. Salaun, P. Romero, S. Lebecque, Toll-like receptors' two-edged sword: when immunity 
meets apoptosis, European journal of immunology, 37 (2007) 3311-3318. 
[64] N.M. Wagner, L. Bierhansl, G. Noldge-Schomburg, B. Vollmar, J.P. Roesner, Toll-like 
receptor 2-blocking antibodies promote angiogenesis and induce ERK1/2 and AKT signaling via 
CXCR4 in endothelial cells, Arterioscler Thromb Vasc Biol, 33 (2013) 1943-1951. 
[65] K. Takeda, S. Akira, Toll-like receptors, Current protocols in immunology / edited by John 
E. Coligan ... [et al.], Chapter 14 (2007) Unit 14 12. 
[66] S. Dimmeler, I. Fleming, B. Fisslthaler, C. Hermann, R. Busse, A.M. Zeiher, Activation of 
nitric oxide synthase in endothelial cells by Akt-dependent phosphorylation, Nature, 399 
(1999) 601-605. 
[67] M. Noguchi, N. Hirata, F. Suizu, The links between AKT and two intracellular proteolytic 
cascades: ubiquitination and autophagy, Biochim Biophys Acta, 1846 (2014) 342-352. 
[68] M.M. Mihaylova, R.J. Shaw, The AMPK signalling pathway coordinates cell growth, 
autophagy and metabolism, Nat Cell Biol, 13 (2011) 1016-1023. 
[69] Y. Ido, D. Carling, N. Ruderman, Hyperglycemia-induced apoptosis in human umbilical vein 
endothelial cells: inhibition by the AMP-activated protein kinase activation, Diabetes, 51 (2002) 
159-167. 
[70] R. Villalobos-Labra, L. Silva, M. Subiabre, J. Araos, R. Salsoso, B. Fuenzalida, T. Saez, F. 
Toledo, M. Gonzalez, C. Quezada, F. Pardo, D.I. Chiarello, A. Leiva, L. Sobrevia, Akt/mTOR Role 
in Human Foetoplacental Vascular Insulin Resistance in Diseases of Pregnancy, J Diabetes Res, 
















[71] A.M. Sutherland, K.R. Walley, Bench-to-bedside review: Association of genetic variation 

















Figure legends  
 
Figure 1. Extracellular histones decrease cell viability and induce apoptosis. 
HUVEC were exposed to increasing concentrations of histones (0-100 μg/mL) for 4 h. 
(A) Percentage of living cells and (B) apoptotic cells were measured by flow cytometry 
from five independent experiments and represented from a total of 4.000 events to 
each sample. The significance has been considered from the value of 0 g/mL samples 
in each condition (**P<0.01 and ***P<0.001). (C) Bright field images recorded by 
Nikon's inverted eclipse Ti microscope (magnification x100) reveal alterations in cell 
morphology. (D) Cell apoptosis was further corroborated by labeling HUVEC with 
Annexin-V-PE. Counterstaining was achieved by DAPI staining. Images are 
representative of five independent experiments recorded by Nikon's inverted eclipse Ti 
microscope (magnification x40). 
Figure 2. Analysis of autophagy flux in HUVEC at different concentration of 
extracellular histones. Protein extracts from cultured HUVEC incubated at different 
concentrations of histones (0-100 μg/mL) during 4 h were loaded on SDS-PAGE gels 
and analyzed by Western blotting using anti-LC3 and anti--actin as a loading control 
(A) To study autophagy flux cellular extracts were obtained without (left panel) or with 
(central panel) lysosomal inhibitors (20 mM NH4Cl plus 0.1 mM leupeptin). 
Densitometry of LC3-II bands from three independent experiments with lysosomal 
inhibitors are shown at the right. The significance has been considered from the value 
of 0 g/mL samples in each condition (**P<0.01 and ***P<0.001). (B) Fluorescence 
microscopy images of LC3 in HUVEC incubated with histones (0-100 μg/mL). 
Maximum projection images derived from 10 Z axis planes are shown. High 
magnification of representative cells is shown in the inset. Dots correspond to 
autophagosomes. Images are representative of 3 independent experiments recorded 
by Leica TCS SP8 X microscope (magnification x40).   
Figure 3. Analysis of autophagolysosome formation in HUVEC at different 
concentrations of extracellular histones. (A) Levels of LAMP2, a lysosomal marker, 
from HUVEC treated with different concentrations of extracellular histones (0-100 
μg/mL) during 4 h were analyzed by Western blotting. (B) Lysosomal mass detected by 
confocal microscopy of HUVEC incubated with histones (0-100 μg/mL) and analysed 
using Lysotracker Red 50 nM. Images are maximum projection derived from 10 Z axis 
planes and are representative of 3 independent experiments recorded by Leica TCS 
















number of lysosomes per cell (dots per cell were counted in at least 10 HUVEC cells 
using ImageJ software).  
Figure 4. Analysis of regulators of autophagy and apoptosis in HUVEC at 
different concentrations of extracellular histones. 
Upstream and downstream signals to mTOR mediated by proteins involved in 
the activation of autophagy in HUVEC incubated with extracellular histones (0-
100 μg/mL). (A) Representative images of Western blots for -actin, Sestrin2, 
pho-AMPK (T172), AMPK, pho-ULK1 (S555), ULK1, pho-Akt (S473), Akt, pho-
mTOR (S2448), mTOR, pho-P70S6K (T389) and P70S6K. (B) Densitometry 
analysis of Sestrin2, pho-AMPK/AMPK, pho-ULK1/ULK1, pho-Akt/AKT, and 
pho-P70S6K/P70S6K ratios. Data represent the mean from three independent 
experiments and statistical significance refers to the value of control samples 
(**P<0.01 and ***P<0.001). (C) Regulation of apoptosis was analyzed by 
Western blotting using the anti-apoptotic marker Bcl-2 and pro-apoptotic 
markers pho-p53 (S15) and Bax. (D) Densitometry analysis of Bax/Bcl-2 ratio to 
evaluate apoptosis flux. Data represent the mean from three independent 
experiments and statistical significance refers to the value of control samples 
(*P<0.05 and **P<0.01). 
 
Figure 5. Effect of TLR inhibitors on apoptosis and autophagy in HUVEC 
exposed to different concentration of extracellular histones. (A) TLR 
inhibitors (30 µM OxPAPC, an inhibitor of TLR-2 and TLR-4, 0.7 µM iODN, a 
TLR-7/9 antagonist, and 3 µM of CLI-095, a TLR-4 antagonist) in HUVEC 
exposed to extracellular histones. Apoptosis and necrosis was assessed by flow 
cytometry analysis by labelling HUVEC using Annexin-V and Propidium iodide. 
Data represent the mean from five independent experiments and statistical 
significance refers to the value of control samples (HUVEC without incubation of 
extracellular histones nor TLR inhibitors (*P<0.05 and **P<0.01). MeanSD for 
viable, apoptotic and necrotic cells and p values for each condition analysed are 
shown in Table 1 and Table 2. (B) Western blotting using anti-LC3 in presence 
of lysosomal inhibitors to analyse autophagy activation in HUVEC treated with 
















anti-LC3 in presence of lysosomal inhibitors to analyse autophagy activation in 
HUVEC incubated with 100 g/mL histones in presence of TLR inhibitors. 
Densitometric analyses from three independent experiments of LC3-II 
normalized levels versus -actin determined by Western blotting, are shown in 
the bottom panel. The significance has been considered from the value of 0 
g/mL samples in each condition (*P<0.05, **P<0.01 and ***P<0.001) 
 
Figure 6.  Influence of extracellular histones on autophagy and apoptosis 
regulators. Scheme summarizing the levels of different autophagy and 
apoptosis regulators after treatment with extracellular histones, showing the 
relationships among them, and the net result in autophagy activation (left) or 
apoptosis activation (right). Treatments between 10 and 100 µg/mL extracellular 
histones result in both an increase in sestrin2 levels (with the consequent 
increase in phospho-AMPK and phospho-ULK1), and a decrease in phospho-
Akt, resulting in an inactivation of mTOR, which correlates with a decrease in 
the phosphorylation of p70S6K, all of it leading to autophagy activation. On the 
other side, only under exposition to 100 µg/mL of histones levels of phospho-
p53 increase, as well as the ratio Bax/Bcl2, leading to activation of apoptotic 
pathways. Moreover, an increase in p53 activation could also contribute to 













Table 1. Effect of extracellular histones on HUVEC pre-incubated with TLR inhibitors. Table shows the % of viable, apoptotic, 
necrotic and apoptotic+necrotic cells. A One-way ANOVA tests were conducted in order to explore significant differences into each group, 
established in base of extracellular histones concentration and comparing the effect of TLR inhibitors. For comparisons with p values lower than 
0.05, Tukey post-hoc tests were performed. MeanSD and data p value for each condition and comparison consisting in five 
independent experiments is shown.  
[Histone]  Condition 
% Viable cells % Apoptotic cells % Necrotic cells % Apoptotic+Necrotic cells 
Mean  SD p value Mean SD p value Mean SD p value Mean SD p value 
0 µg/µL 
Control 89.44 4.23 - 9.66 3.91 - 0.77 0.59 - 10.44 4.29 - 
OxPAPC 77.44 8.09 0.010 20.69 8.81 0.026 1.86 081 0.026 22.56 8.08 0.010 
iODN 84.83 5.48 >0.05 13.94 5.73 >0.05 1.24 0.77 >0.05 15.13 6.13 >0.05 
CLI-95 79.39 3.04 0.001 19.13 3.64 0.006 1.48 0.77 >0.05 20.61 3.03 0.001 
50 µg/µL 
 
Control 82.96 4.84 - 15.65 4.82 - 1.08 0.57 - 16.63 4.45 - 
OxPAPC 82.55 0.014 >0.05 14.83 1.66 >0.05 2.61 1.67 >0.05 17.45 0.014 0.044 
iODN 86.68 5.33 >0.05 12.00 6.22 >0.05 1.32 1.40 >0.05 13.32 5.33 >0.05 
CLI-95 69.83 3.35 0.005 29.65 3.11 0.003 0.52 0.23 >0.05 30.17 3.04 0.002 
100 µg/µL 
 
Control 78.50 2.99 - 19.64 2.28 - 2.29 1.22 - 21.93 3.27 - 
OxPAPC 54.61 6.58 0.010 40.44 6.06 0.011 4.94 2.89 >0.05 45.38 6.58 0.011 
iODN 73.11 8.14 >0.05 21.91 5.07 >0.05 4.98 3.23 >0.05 26.89 8.13 >0.05 














Table 2. Effect of extracellular histones on HUVEC pre-incubated with TLR inhibitors. Table shows the % of viable, apoptotic, 
necrotic and apoptotic+necrotic cells. One-way ANOVA tests were conducted in order to explore significant differences into each group, 
established in base of TLR inhibitors and comparing the effect of different extracellular histones concentration. For comparisons with p values 
lower than 0.05, Tukey post-hoc tests were performed.  MeanSD and data p value for each condition and comparison consisting in five 




































































































































































































































0 77.40 8.09 - n.s 0.005 20.69  8.81 - n.s 0.013 1.86 0.80 - n.s n.s 22.56 8.08 - n.s 0.005 
50 82.55 0.01 n.s - 0.005 14.83 1.66 n.s - 0.010 2.61 1.67 n.s - n.s 17.45 0.01 n.s - 0.005 
100 
 





84.82 5.48 - n.s 0.036 13.93 5.73 - n.s n.s 1.24 0.77 - n.s 
0.02
8 
15.17 5.33 - n.s 0.036 
50 
86.68 5.33 n.s - 0.027 12.00 6.22 n.s - n.s 1.32 1.40 n.s - 
0.04
9 
13.32 5.33 n.s - 0.027 
100 
 




0 79.39 3.04 - n.s 0.003 19.13 3.40 - n.s 0.042 1.48 0.77 - n.s n.s 20.61 3.34 - n.s 0.031 
50 
69.83 3.51 n.s - n.s 29.65 3.11 n.s - n.s 0.52 0.23 n.s - 
0.01
3 
30.17 3.34 n.s - n.s 
100 
 
61.44 6.49 0.003 n.s - 34.19 9.80 0.042 n.s - 2.39 0.26 n.s 0.013 - 36.58 9.80 0.031 n.s - 
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